Over 180 companies from different regions across the globe presently claim to provide services for the development of co


To order this 320+ page report, which features 120+ figures and 115+ tables, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

.

It is estimated that around 80% of innovator companies rely on external companion diagnostic developers, mostly owing to the lack of the required in-house expertise. On the other hand, there are numerous contract service providers, offering vast portfolios of services for diagnostic test / assay development. Such companies are known to possess extensive technical knowledge, and experience in working with cutting-edge analytical tools and technologies, such as in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR).

 

To  order this 320+ page report, which features 120+ figures and 115+ tables, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

 

The USD 800+ million (by 2030) financial opportunity within the companion diagnostics development services market has been analysed across the following segments:

  • Type of Service Offered
  • Feasibility Studies
  • Assay Development
  • Analytical Validation
  • Clinical Validation

 

  • Type of Assay Technique Used
  • in situ hybridization / Immunohistochemistry
  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Others

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific

 

 

The report features inputs from eminent industry stakeholders, according to whom the development of companion diagnostics is largely outsourced, owing to the exorbitant costs associated with the setting-up of in-house expertise / capabilities. The report includes detailed transcripts of discussions held with the following experts:

  • Anton Iliuk (President and Chief Technology Officer, Tymora Analytica)
  • Paul Kortschak (Senior Vice President, Novodiax)
  • Pablo Ortiz (Chief Executive officer, OWL Metabolomics)
  • Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

 

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction
  3. Market Landscape
  4. Company Profiles

 

  1. Partnerships and Collaborations
  2. Likely Partner Analysis
  3. Company Competitiveness Analysis
  4. Stakeholder Needs Analysis
  5. Value Chain Analysis

 

  1. Clinical Research on Cancer Biomarkers: Big Pharma Perspective

 

  1. Market Forecast And Opportunity Analysis

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/